BioSig Technologies, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Medical Specialties
DHRDanaher Corp. 0.98%163.090.7%$520.18m
MDTMedtronic Plc 0.13%119.010.6%$396.86m
ABTAbbott Laboratories 0.83%89.010.8%$362.86m
ISRGIntuitive Surgical, Inc. 0.29%600.032.4%$362.07m
TMOThermo Fisher Scientific, Inc. 0.71%339.141.0%$288.79m
BSXBoston Scientific Corp. 2.50%44.281.1%$284.80m
BDXBecton, Dickinson & Co. 0.08%277.091.1%$261.39m
SYKStryker Corp. 1.25%212.081.3%$248.97m
ABMDABIOMED, Inc. -0.09%181.283.3%$209.66m
EWEdwards Lifesciences Corp. -0.05%238.461.2%$209.38m
BAXBaxter International, Inc. -0.29%89.731.8%$205.14m
ALGNAlign Technology, Inc. -1.52%280.706.4%$195.31m
STESTERIS Plc (Ireland) -0.06%154.043.7%$171.56m
DXCMDexCom, Inc. -1.54%230.798.3%$168.83m
NVSTEnvista Holdings Corp. 0.25%32.020.0%$142.47m

Company Profile

BioSig Technologies, Inc. is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company is preparing to commercialize its PURE EPâ„¢ System. The technology has been developed to address an unmet need in a large and growing market. Its first product, PURE EPâ„¢ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. Its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Los Angeles, CA.